PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Clinical trials for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA explained in plain language.
Never miss a new study
Get alerted when new PAROXYSMAL NOCTURNAL HEMOGLOBINURIA trials appear
Sign up with your email to follow new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Korean health officials track real-world safety of new PNH combo therapy
Disease control Recruiting nowThis study monitors the safety and effectiveness of Danicopan when used alongside standard PNH treatments (ravulizumab or eculizumab) in routine Korean medical practice. It involves 8 participants and aims to confirm known side effects or detect new ones, as well as measure chang…
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Sponsor: AstraZeneca • Aim: Disease control
Last updated May 26, 2026 07:56 UTC
-
New hope for PNH patients failing standard therapy: experimental combo enters phase 3
Disease control Recruiting nowThis study tests two experimental drugs, pozelimab and cemdisiran, in 35 adults with paroxysmal nocturnal hemoglobinuria (PNH) whose disease is still active despite standard C5 inhibitor therapy. The goal is to see if the combination can better control red blood cell destruction …
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 07:53 UTC
-
New hope for PNH patients: experimental drug HS-10542 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called HS-10542 in adults with paroxysmal nocturnal hemoglobinuria (PNH) who still have signs of active red blood cell breakdown despite current treatment. About 50 participants aged 18 to 75 will receive the drug to see if it is safe and can…
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 07:52 UTC
-
New hope for PNH patients: early access to danicopan for hard-to-treat anemia
Disease control AVAILABLEThis program provides early access to danicopan for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have significant extravascular hemolysis (EVH) despite current treatment with Soliris or Ultomiris. Participants must be at least 18 years old, have anemia and high retic…
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New hope for kids with rare blood disease: Add-On pill may boost red blood cells
Disease control Recruiting nowThis study tests whether adding danicopan (a pill) to standard PNH therapy (ravulizumab or eculizumab) can improve hemoglobin levels in children aged 12 to 17 with paroxysmal nocturnal hemoglobinuria (PNH) who still have anemia due to extravascular hemolysis. About 6 participants…
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 18, 2026 12:12 UTC
-
New drug iptacopan tested for rare blood disorder in china
Disease control Recruiting nowThis study looks at how well the drug iptacopan works for adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Researchers will track changes in hemoglobin levels and other health outcomes over time. About 80 participants in China who have never taken sim…
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 18, 2026 12:02 UTC
-
New drug combo aims to control rare blood disease Long-Term
Disease control Recruiting nowThis study is for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. It tests the long-term safety and effectiveness of two experimental drugs, pozelimab and cemdisiran, taken together. About 202 participants will receive the combination therapy to see …
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 14, 2026 12:06 UTC